acamprosate vs lisdexamfetamine
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acamprosate and lisdexamfetamine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Campral
Vyvanse
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking. It should be used with counseling and support.
Lisdexamfetamine (Vyvanse) is a stimulant medicine. It can help improve focus and reduce impulsive behavior.
Acamprosate helps people who are alcohol-dependent to not drink alcohol. You must have already stopped drinking before you start taking acamprosate. This medicine works best when it is part of a complete treatment plan that includes counseling and support.
This medicine treats Attention Deficit Hyperactivity Disorder (ADHD) in adults and kids 6 years and older. It also treats moderate to severe binge eating disorder (BED) in adults. This medicine is not for weight loss.
Acamprosate is similar to a natural substance in your brain. It is thought to work by helping to restore the normal balance of brain activity that is changed by long-term alcohol use. This can reduce your craving for alcohol.
Lisdexamfetamine affects chemicals in your brain. These chemicals help control hyperactivity and impulses. It can also help reduce binge eating.
- • Accidental injury
- • Weakness
- • Pain
- • Loss of appetite
- • Diarrhea
- • Anorexia
- • Anxiety
- • Decreased appetite
- • Weight loss
- • Diarrhea
- Hypotension 14
- Asthenia 13
- Condition Aggravated 13
- Acute Kidney Injury 12
- Coma 12
- Intentional Overdose 1,068
- Intentional Self-Injury 1,009
- Product Availability Issue 487
- Fatigue 402
- Headache 377
Acamprosate may increase the risk of suicidal thoughts or actions. Your doctor should watch you for depression or suicidal thoughts. Tell your doctor right away if you have any new or worsening symptoms of depression or suicidal thoughts.
This medicine has a high risk for abuse, misuse, and addiction. Misusing it can lead to overdose and death. Your doctor will check your risk before and during treatment. Store this medicine safely and do not share it with anyone.
Acamprosate may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acamprosate passes into breast milk. Talk to your doctor if you are breastfeeding.
This medicine may harm your unborn baby. Tell your doctor if you are pregnant or plan to become pregnant. Breastfeeding is not recommended while taking this medicine.
Also Compare, Nearby Drugs
Compare lisdexamfetamine with
How to Read This acamprosate vs lisdexamfetamine Comparison
acamprosate is classified in the GABA Analog (Alcohol Dependence) drug class, while lisdexamfetamine sits within the CNS Stimulant class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acamprosate has 64 submissions while lisdexamfetamine has 3,343. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acamprosate or lisdexamfetamine.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.